Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site

Molecular Oncology

Volumn 1, Issue 4, 2008, Pages 395-405

  Platz, Anton ^a   Egyhazi, Suzanne ^a   Ringborg, Ulrik ^a   Hansson, Johan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

BRAF; Classification; Malignant melanoma; Mutation; NRAS; Sunlight; UV radiation

Indexed keywords

B RAF KINASE; RAF PROTEIN; RAS PROTEIN;

BODY SIZE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER RISK; GENOTOXICITY; HISTOGENESIS; HUMAN; MELANOMA; MUTAGENESIS; MUTATION; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; SIGNAL TRANSDUCTION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION;

GENES, RAS; HUMANS; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 40849094167     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2007.12.003     Document Type: Review

References (88)

1. Akslen L.A., Angelini S., Straume O., Bachmann I.M., Molven A., Hemminki K., and Kumar R. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J. Invest. Dermatol. 125 (2005) 312-317
2. Albino A.P., Le Strange R., Oliff A.I., Furth M.E., and Old L.J. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?. Nature 308 (1984) 69-72
3. Albino A.P., Nanus D.M., Mentle I.R., Cordon-Cardo C., McNutt N.S., Bressler J., and Andreeff M. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 4 (1989) 1363-1374
4. Alsina J., Gorsk D.H., Germino F.J., Shih W., Lu S.E., Zhang Z.G., Yang J.M., Hait W.N., and Goydos J.S. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin. Cancer Res. 9 (2003) 6419-6425
5. Ball N.J., Yohn J.J., Morelli J.G., Norris D.A., Golitz L.E., and Hoeffler J.P. Ras mutations in human melanoma: a marker of malignant progression. J. Invest. Dermatol. 102 (1994) 285-290
6. Barbacid M. Ras genes. Annu. Rev. Biochem. 56 (1987) 779-827
7. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689
8. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62 (2002) 6997-7000
9. Carr J., and Mackie R.M. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br. J. Dermatol. 131 (1994) 72-77
10. Chin L., Pomerantz J., Polsky D., Jacobson M., Cohen C., Cordon-Cardo C., Horner II J.W., and DePinho R.A. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11 (1997) 2822-2834
11. Christensen C., and Guldberg P. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene 24 (2005) 6292-6302
12. Chudnovsky Y., Adams A.E., Robbins P.B., Lin Q., and Khavari P.A. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat. Genet. 37 (2005) 745-749
13. Cruz III F., Rubin B.P., Wilson D., Town A., Schroeder A., Haley A., Bainbridge T., Heinrich M.C., and Corless C.L. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 63 (2003) 5761-5766
14. Curtin J.A., Fridlyand J., Kageshita T., Patel H.N., Busam K.J., Kutzner H., Cho K.H., Aiba S., Brocker E.B., LeBoit, et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med 353 (2005) 2135-2147
15. Curtin J.A., Busam K., Pinkel D., and Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol 24 (2006) 4340-4346
16. Daniotti M., Oggionni M., Ranzani T., Vallacchi V., Campi V., Di Stasi D., Torre G.D., Perrone F., Luoni C., Suardi S., et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23 (2004) 5968-5977
17. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
18. Daya-Grosjean L., Dumaz N., and Sarasin A. The specificity of p53 mutation spectra in sunlight induced human cancers. J. Photochem. Photobiol. B 28 (1995) 115-124
19. Deichmann M., Thome M., Benner A., and Naher H. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology 66 (2004) 411-419
20. Demunter A., Ahmadian M.R., Libbrecht L., Stas M., Baens M., Scheffzek K., Degreef H., De Wolf-Peeters C., and van Den Oord J.J. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 61 (2001) 4916-4922
21. Demunter A., Stas M., Degreef H., De Wolf-Peeters C., and van den Oord J.J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol 117 (2001) 1483-1489
22. Denhardt D.T. Signal transduction pathways and regulation of the mammalian cell cycle: cell type-dependent integration of external signals. In: Stein G.S., Baserga R., Giordano A., and Denhardt D.T. (Eds). The Molecular Basis of Cell Cycle and Growth Control (1998), Wiley, New York 225-304
23. Dong J., Phelps R.G., Qiao R., Yao S., Benard O., Ronai Z., and Aaronson S.A. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 63 (2003) 3883-3885
24. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
25. Dumaz N., Hayward R., Martin J., Ogilvie L., Hedley D., Curtin J.A., Bastian B.C., Springer C., and Marais R. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66 (2006) 9483-9491
26. Edlundh-Rose E., Egyha Zi S., Omholt K., Mansson-Brahme E., Platz A., Hansson J., and Lundeberg J. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 16 (2006) 471-478
27. Edwards R.H., Ward M.R., Wu H., Medina C.A., Brose M.S., Volpe P., Nussen-Lee S., Haupt H.M., Martin A.M., Herlyn M., et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J. Med. Genet. 41 (2004) 270-272
28. Elwood J.M., and Jopson J. Melanoma and sun exposure: an overview of published studies. Int. J. Cancer 73 (1997) 198-203
29. van Elsas A., Zerp S.F., van der Flier S., Kruse K.M., Aarnoudse C., Hayward N.K., Ruiter D.J., and Schrier P.I. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol 149 (1996) 883-893
30. Eskandarpour M., Hashemi J., Kanter L., Ringborg U., Platz A., and Hansson J. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J. Natl. Cancer Inst 95 (2003) 790-798
31. Eskandarpour M., Kiaii S., Zhu C., Castro J., Sakko A.J., and Hansson J. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int. J. Cancer 115 (2005) 65-73
32. Goel V.K., Lazar A.J., Warneke C.L., Redston M.S., and Haluska F.G. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol 126 (2006) 154-160
33. Gorden A., Osman I., Gai W., He D., Huang W., Davidson A., Houghton A.N., Busam K., and Polsky D. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 63 (2003) 3955-3957
34. Goydos J.S., Mann B., Kim H.J., Gabriel E.M., Alsina J., Germino F.J., Shih W., and Gorski D.H. Detection of B-RAF and N-RAS mutations in human melanoma. J. Am. Coll. Surg 200 (2005) 362-370
35. Grafström E., Egyhazi S., Ringborg U., Hansson J., and Platz A. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin. Cancer Res. 11 (2005) 2991-2997
36. Gray-Schopfer V.C., Karasarides M., Hayward R., and Marais R. TNFa blocks apoptosis in melanoma cells when BRAF signalling is inhibited. Cancer Res. 67 (2007) 122-129
37. Hanneman K.K., Cooper K.D., and Baron E.D. Ultraviolet immunosuppression: mechanisms and consequences. Dermatol. Clin 24 (2006) 19-25
38. Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., and Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63 (2003) 5198-5202
39. Hocker T., and Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat 28 (2007) 578-588
40. Houben R., Becker J.C., Kappel A., Terheyden P., Brocker E.B., Goetz R., and Rapp U.R. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog 3 (2004) 6
41. Husain Z., Pathak M.A., Flotte T., and Wick M.M. Role of ultraviolet radiation in the induction of melanocytic tumors in hairless mice following 7,12-dimethylbenz(a)anthracene application and ultraviolet irradiation. Cancer Res. 51 (1991) 4964-4970
42. Ito K., and Kawanishi S. Site-specific DNA damage induced by UVA radiation in the presence of endogenous photosensitizer. Biol. Chem. 378 (1997) 1307-1312
43. Jafari M., Papp T., Kirchner S., Diener U., Henschler D., Burg G., and Schiffmann D. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J. Cancer Res. Clin. Oncol 121 (1995) 23-30
44. Jiveskog S., Ragnarsson-Olding B., Platz A., and Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol 111 (1998) 757-761
45. Joshi P.C., Carraro C., and Pathak M.A. Involvement of reactive oxygen species in the oxidation of tyrosine and dopa to melanin and in skin tanning. Biochem. Biophys. Res. Commun 142 (1987) 265-274
46. Kumar R., Angelini S., and Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 22 (2003) 9217-9224
47. Kumar R., Angelini S., Czene K., Sauroja I., Hahka-Kemppinen M., Pyrhönen S., and Hemminki K. BRAF Mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 9 (2003) 3362-3368
48. Landi M.T., Bauer J., Pfeiffer R.M., Elder D.E., Hulley B., Minghetti P., Calista D., Kanetsky P.A., Pinkel D., and Bastian B.C. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313 (2006) 521-522
49. Lang J., and MacKie R.M. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J. Invest. Dermatol 125 (2005) 575-579
50. Lassacher A., Worda M., Kaddu S., Heitzer E., Legat F., Massone C., Cerroni L., Kerl H., Ananthaswamy H.N., and Wolf P. T1799A BRAF mutation is common in PUVA lentigines. J. Invest. Dermatol 126 (2006) 1915-1917
51. Lupetti R., Sensi M., Mortarini R., Anichini A., Clemente C., and Parmiani G. N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma. Melanoma Res. 4 (1994) 11-19
52. Maldonado J.L., Fridlyand J., Patel H., Jain A.N., Busam K., Kageshita T., Ono T., Albertson D.G., Pinkel D., and Bastian B.C. Determinants of BRAF mutations in primary melanomas. J. Natl. Cancer Inst 95 (2003) 1878-1890
53. Martin G.S. Cell signaling and cancer. Cancer Cell 4 (2003) 167-174
54. Meier F., Schittek B., Busch S., Garbe C., Smalley K., Satyamoorthy K., Li G., and Herlyn M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10 (2005) 2986-3001
55. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., and Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
56. Nappi A.J., and Vass E. Hydrogen peroxide generation associated with the oxidations of the eumelanin precursors 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. Melanoma Res. 6 (1996) 341-349
57. Omholt K., Karsberg S., Platz A., Kanter L., Ringborg U., and Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin. Cancer Res. 8 (2002) 3468-3474
58. Omholt K., Platz A., Kanter L., Ringborg U., and Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9 (2003) 6483-6488
59. Padua R.A., Barrass N.C., and Currie G.A. Activation of N-ras in a human melanoma cell line. Mol. Cell. Biol. 5 (1985) 582-585
60. Peyssonnaux C., and Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell 93 (2001) 53-62
61. Pierceall W.E., Kripke M.L., and Ananthaswamy H.N. N-ras mutation in ultraviolet radiation-induced murine skin cancers. Cancer Res. 52 (1992) 3946-3951
62. Platz A., Ringborg U., Brahme E.M., and Lagerlof B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res. 4 (1994) 169-177
63. Platz A., Ringborg U., Grafstrom E., Hoog A., and Lagerlof B. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res. 5 (1995) 101-106
64. Pollock P.M., and Meltzer P.S. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2 (2002) 5-7
65. Pollock P.M., Harper U.L., Hansen K.S., Yudt M.L., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., et al. High frequency of BRAF mutations in nevi. Nat. Genet 33 (2003) 19-20
66. Poynter J.N., Elder J.T., Fullen D.R., Nair R.P., Soengas M.S., Johnson T.M., Redman B., Thomas N.E., and Gruber S.B. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 16 (2006) 267-273
67. Reifenberger J., Knobbe C.B., Sterzinger A.A., Blaschke B., Schulte K.W., Ruzicka T., and Reifenberger G. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int. J. Cancer 109 (2004) 377-384
68. Repasky G.A., Chenette E.J., and Der C.J. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol. 14 (2004) 639-647
69. Saldanha G., Purnell D., Fletcher A., Potter L., Gillies A., and Pringle J.H. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int. J. Cancer 111 (2004) 705-710
70. Satyamoorthy K., Li G., Gerrero M.R., Brose M.S., Volpe P., Weber B.L., Van Belle P., Elder D.E., and Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63 (2003) 756-759
71. Sekiya T., Fushimi M., Hori H., Hirohashi S., Nishimura S., and Sugimura T. Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient. Proc. Natl. Acad. Sci. USA 81 (1984) 4771-4775
72. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
73. Shields J.M., Pruitt K., McFall A., Shaub A., and Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10 (2000) 147-154
74. Shinozaki M., Fujimoto A., Morton D.L., and Hoon D.S. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res. 10 (2004) 1753-1757
75. Shukla V.K., Hughes D.C., Hughes L.E., McCormick F., and Padua R.A. ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res. 5 (1989) 121-127
76. Sivertsson A., Platz A., Hansson J., and Lundeberg J. Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. Clin. Chem. 48 (2002) 2164-2170
77. Thomas N.E., Alexander A., Edmiston S.N., Parrish E., Millikan R.C., Berwick M., Groben P., Ollila D.W., Mattingly D., and Conway K. Tandem BRAF mutations in primary invasive melanomas. J. Invest. Dermatol 122 (2004) 1245-1250
78. Thomas N.E., Berwick M., and Cordeiro-Stone M. Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation?. J. Invest. Dermatol 126 (2006) 1693-1696
79. Törmänen V.T., and Pfeifer G.P. Mapping of UV photoproducts within ras proto-oncogenes in UV-irradiated cells: correlation with mutations in human skin cancer. Oncogene 7 (1992) 1729-1736
80. Trahey M., and McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238 (1987) 542-545
81. Tsao H., Goel V., Wu H., Yang G., and Haluska F.G. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122 (2004) 337-341
82. Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A., Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R., et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS one 2 (2007) e236. http://www.plosone.org
83. Uribe P., Wistuba I.I., and Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am. J. Dermatopathol 25 (2003) 365-370
84. Van der Lubbe J.L., Rosdorff H.J., Bos J.L., and Van der Eb A.J. Activation of N-ras induced by ultraviolet irradiation in vitro. Oncogene Res. 3 (1988) 9-20
85. van't Veer L.J., Burgering B.M., Versteeg R., Boot A.J., Ruiter D.J., Osanto S., Schrier P.I., and Bos J.L. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell Biol. 9 (1989) 3114-3116
86. Wellbrock C., Ogilvie L., Hedley D., Karasarides M., Martin J., Niculescu-Duvaz D., Springer C.J., and Marais R. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64 (2004) 2338-2342
87. Whitwam T., VanBrocklin M.W., Russo M.E., Haak P.T., Bilgili D., Resau R.H., Koo H.M., and Holmen S.L. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene 26 (2007) 4563-4570
88. Zhang B.H., and Guan K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. Embo J 19 (2000) 5429-5439